Chung Yin Kong

List of Publications by Year
in descending order

109 papers	5,269 citations	117625 34 h-index	91884 69 g-index
110 all docs	110 docs citations	110 times ranked	6205 citing authors

#	Article	IF	Citations
1	Factors Influencing the False Positive Rate in CT Lung Cancer Screening. Academic Radiology, 2022, 29, S18-S22.	2.5	16
2	Cost-Effectiveness of Follow-Up Ultrasound for Incidental Thyroid Nodules on CT. American Journal of Roentgenology, 2022, 218, 615-622.	2.2	4
3	Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy. Chest, 2022, 161, 1666-1674.	0.8	2
4	Costâ€effectiveness of neoadjuvant <scp>FOLFIRINOX</scp> versus gemcitabine plus nabâ€paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 2022, 5, e1565.	1.4	4
5	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 2022, 163, 163-173.	1.3	7
6	Lung cancer incidence among world trade center rescue and recovery workers. Cancer Medicine, 2022, 11, 3136-3144.	2.8	3
7	Impact of Comorbidities on Lung Cancer Screening Evaluation. Clinical Lung Cancer, 2022, 23, 402-409.	2.6	3
8	Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities. Current Problems in Cancer, 2022, , 100867.	2.0	0
9	Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities. Lung Cancer, 2022, 170, 34-40.	2.0	6
10	Lung cancer treatment patterns in patients with diabetes.. Journal of Clinical Oncology, 2022, 40, e18723-e18723.	1.6	0
11	Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities. PLoS ONE, 2021, 16, e0248067.	2.5	6
12	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. JAMA - Journal of the American Medical Association, 2021, 325, 988.	7.4	181
13	Cost-Effectiveness of Management Algorithms for Lung-RADS Category 4 Nodules. Radiology: Cardiothoracic Imaging, 2021, 3, e200523.	2.5	2
14	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, e16246-e16246.	1.6	0
15	Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening. Radiology, 2021, 300, 586-593.	7.3	9
16	Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study. Journal of the National Cancer Institute, 2021, 113, 1065-1073.	6.3	34
17	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncology, 2021, 7, 1833.	7.1	29
18	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. Journal of the National Cancer Institute, 2020, 112, 466-479.	6.3	67

#	Article	IF	Citations
19	Optimizing Management of Patients With Barrettâ€™s Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. Clinical Gastroenterology and Hepatology, 2020, 18, 1961-1969.	4.4	15
20	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2020, 172, 706-707.	3.9	2
21	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine, 2020, 383, 640-649.	27.0	893
22	Performance of Lung Nodule Management Algorithms for Lung-RADS Category 4 Lesions. Academic Radiology, 2020, 28, 1037-1042.	2.5	9
23	Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Medicine, 2020, 18, 257.	5.5	37
24	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. JAMA Network Open, 2020, 3, e2016144.	5.9	24
25	Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States. Oncologist, 2020, 25, e120-e129.	3.7	20
26	Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. PLoS ONE, 2020, 15, e0228288.	2.5	12
27	Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients. Journal of Thoracic Oncology, 2020, 15, 1298-1305.	1.1	9
28	Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. PLoS ONE, 2020, 15, e0231599.	2.5	38
29	Esophageal cancer treatment costs by phase of care and treatment modality, 2000â€2013. Cancer Medicine, 2019, 8, 5158-5172.	2.8	21
30	A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea. PLoS ONE, 2019, 14, e0220610.	2.5	5
31	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer in the United States. JAMA Network Open, 2019, 2, e1911952.	5.9	47
32	Cancer Risk in Subsolid Nodules in the National Lung Screening Trial. Radiology, 2019, 293, 441-448.	7.3	47
33	The effect of radiographic emphysema in assessing lung cancer risk. Thorax, 2019, 74, 858-864.	5.6	24
34	Development and validation of a model to predict outcomes of colon cancer surveillance. Cancer Causes and Control, 2019, 30, 767-778.	1.8	3
35	Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancerâ€”In Reply. JAMA Oncology, 2019, 5, 1066.	7.1	1
36	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS ONE, 2019, 14, e0215409.	2.5	7

#	Article	IF	Citations
37	Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Nonâ€“Small Cell Lung Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 926-934.	2.5	27
38	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results. JAMA Network Open, 2019, 2, e190204.	5.9	70
39	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2019, 171, 796.	3.9	81
40	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000â€“2013. Medicine (United States), 2019, 98, e18082.	1.0	13
41	Short-term outcomes for lung cancer resection surgery in HIV infection. Aids, 2019, 33, 1353-1360.	2.2	9
42	Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Medicine, 2019, 8, 94-103.	2.8	54
43	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 180.e11-180.e18.	1.6	12
44	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist, 2019, 24, 945-954.	3.7	13
45	A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules. Radiology, 2019, 290, 506-513.	7.3	17
46	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. American Journal of Roentgenology, 2019, 212, 596-601.	2.2	4
47	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Nonâ€“Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncology, 2019, 5, 358.	7.1	48
48	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Medicine, 2018, 7, 525-535.	2.8	136
49	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 392-400.e7.	4.4	17
50	Re: Think before you leap. International Journal of Cancer, 2018, 142, 1507-1509.	5.1	0
51	Patterns and predictors of endâ€ofâ€life care in older patients with pancreatic cancer. Cancer Medicine, 2018, 7, 6401-6410.	2.8	20
52	Analysis of factors associated with extended recovery time after colonoscopy. PLoS ONE, 2018, 13, e0199246.	2.5	4
53	Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. Annals of Internal Medicine, 2018, 169, 684.	3.9	150
54	Hospice use and endâ€ofâ€life care among older patients with esophageal cancer. Health Science Reports, 2018, 1, e76.	1.5	16

#	Article	IF	Citations
55	Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology, 2018, 18, 928-934.	1.1	32
56	Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/Î¼l. Aids, 2018, 32, 1333-1342.	2.2	35
57	Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. Digestive Diseases and Sciences, 2018, 63, 2880-2888.	2.3	18
58	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors.. Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	1
59	Population impact of lung cancer screening in the United States: Projections from a microsimulation model. PLoS Medicine, 2018, 15, e1002506.	8.4	21
60	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.. Journal of Clinical Oncology, 2018, 36, e16089-e16089.	1.6	0
61	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1471-1474.	4.4	20
62	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. International Journal of Cancer, 2017, 140, 2436-2443.	5.1	36
63	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrettâ€™s Esophagus With a Minimally Invasive Cell Sampling Device. Clinical Gastroenterology and Hepatology, 2017, 15, 1397-1404.e7.	4.4	51
64	The Impact of a Prior Diagnosis of Barrettâ€™s Esophagus on Esophageal Adenocarcinoma Survival. American Journal of Gastroenterology, 2017, 112, 1256-1264.	0.4	45
65	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Internal Medicine, 2017, 177, 1613.	5.1	99
66	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Medicine, 2017, 14, e1002277.	8.4	216
67	The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. PLoS ONE, 2017, 12, e0177068.	2.5	5
68	Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. PLoS ONE, 2017, 12, e0173119.	2.5	9
69	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
70	Disparities in cancer outcomes across age, sex, and race/ethnicity among pancreatic cancer patients.. Journal of Clinical Oncology, 2017, 35, e18071-e18071.	1.6	0
71	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size. Pancreas, 2016, 45, 1062-1066.	1.1	33
72	Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. BMJ Open, 2016, 6, e010227.	1.9	16

#	Article	IF	Citations
73	Combined Biomarker and Computed Tomography Screening Strategies for Lung Cancer. MDM Policy and Practice, 2016, 1, 238146831664396.	0.9	4
74	Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. EBioMedicine, 2015, 2, 1980-1986.	6.1	14
75	Identifying Best-Fitting Inputs in Health-Economic Model Calibration. Medical Decision Making, 2015, 35, 170-182.	2.4	17
76	High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. World Journal of Gastroenterology, 2015, 21, 5513.	3.3	13
77	Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer, 2015, 121, 1556-1562.	4.1	23
78	Comparing Morbidities of Testing With a New Index: Screening Colonoscopy Versus Core-Needle Breast Biopsy. Journal of the American College of Radiology, 2015, 12, 295-301.	1.8	12
79	Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. Radiology, 2015, 275, 177-187.	7.3	34
80	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. PLoS ONE, 2014, 9, e99978.	2.5	38
81	Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. Cancer Prevention Research, 2014, 7, 341-350.	1.5	27
82	Imaging for Appendicitis: Should Radiation-induced Cancer Risks Affect Modality Selection?. Radiology, 2014, 273, 472-482.	7.3	10
83	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer, 2014, 120, 1713-1724.	4.1	65
84	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 997-1006.	2.5	61
85	A simulation model of colorectal cancer surveillance and recurrence. BMC Medical Informatics and Decision Making, 2014, 14, 29.	3.0	12
86	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2014, 160, 311.	3.9	377
87	JOURNAL CLUB: How Radiation Exposure Histories Influence Physician Imaging Decisions: A Multicenter Radiologist Survey Study. American Journal of Roentgenology, 2013, 200, 1275-1283.	2.2	23
88	Microsimulation Model Predicts Survival Benefit of Radiofrequency Ablation and Stereotactic Body Radiotherapy Versus Radiotherapy for Treating Inoperable Stage I Nonâ€“Small Cell Lung Cancer. American Journal of Roentgenology, 2013, 200, 1020-1027.	2.2	11
89	Patients with Testicular Cancer Undergoing CT Surveillance Demonstrate a Pitfall of Radiation-induced Cancer Risk Estimates: The Timing Paradox. Radiology, 2013, 266, 896-904.	7.3	35
90	Patient and Societal Value Functions for the Testing Morbidities Index. Medical Decision Making, 2013, 33, 819-838.	2.4	16

#	Article	IF	Citations
91	Trends in esophageal adenocarcinoma incidence and mortality. Cancer, 2013, 119, 1149-1158.	4.1	439
92	Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975â€“2000. Journal of the National Cancer Institute, 2012, 104, 541-548.	6.3	145
93	Using Radiation Risk Models in Cancer Screening Simulations: Important Assumptions and Effects on Outcome Projections. Radiology, 2012, 262, 977-984.	7.3	30
94	Chapter 9: The MGHâ€HMS Lung Cancer Policy Model: Tobacco Control Versus Screening. Risk Analysis, 2012, 32, S117-24.	2.7	37
95	Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. Clinical Gastroenterology and Hepatology, 2012, 10, 722-727.	4.4	57
96	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. Gastroenterology, 2012, 143, 567-575.	1.3	143
97	Quality-of-Life Assessment of Fibroid Treatment Options and Outcomes. Radiology, 2011, 259, 785-792.	7.3	32
98	The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2450-2456.	2.5	38
99	Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States. Journal of Thoracic Oncology, 2011, 6, 1841-1848.	1.1	213
100	Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. Quality of Life Research, 2010, 19, 401-412.	3.1	13
101	Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma. PLoS ONE, 2010, 5, e9483.	2.5	15
102	Projected Costs, Risks, and Benefits of Expanded Newborn Screening for MCADD. Pediatrics, 2010, 125, e286-e294.	2.1	34
103	Convergent Evolution of Novel Protein Function in Shrew and Lizard Venom. Current Biology, 2009, 19, 1925-1931.	3.9	53
104	Calibration of Disease Simulation Model Using an Engineering Approach. Value in Health, 2009, 12, 521-529.	0.3	53
105	Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines. Pharmacoeconomics, 2009, 27, 533-545.	3.3	99
106	Adopting helical CT screening for lung cancer. Cancer, 2008, 113, 3440-3449.	4.1	29
107	Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study. Radiology, 2008, 248, 278-287.	7.3	94
108	Simulations of Stochastic Sensing of Proteins. Journal of the American Chemical Society, 2005, 127, 18252-18261.	13.7	37

#	Article	IF	Citations
109	Tissue scale agent-based simulation of premalignant progressions in Barrettâ€™s esophagus. Simulation, 0, , 003754972110400.	1.8	1